 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Initial interim landmark data analysis (N=50 at 24 Weeks) to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at...

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT  Free Report)  Investment analysts at Chardan Capital boosted their FY2023 earnings per share estimates for shares of 4D Molecular...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Expected to Post FY2023 Earnings of ($2.70) Per Share

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT  Free Report)  Equities research analysts at Cantor Fitzgerald boosted their FY2023 EPS estimates for 4D Molecular Therapeutics in a note...

Cantor Fitzgerald Weighs in on 4D Molecular Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:FDMT)

EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next...

4DMT to Participate in Upcoming Investor Conferences

Chardan Capital analyst Geulah Livshits has reiterated their bullish stance on FDMT stock, giving a Buy rating on November 2. Geulah Livshits has g...

4D Molecular Therapeutics Continues Growth: Q3 Financials and Progress in Ophthalmology Trials Reinforce Buy Rating

Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled...

4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on FDMT stock, giving a Buy rating on November 2. Mani Foroohar's Buy ra...

Buy Rating for 4D Molecular Therapeutics: An Analysis of Potential Growth and Future Prospects

Aerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-upPromising, reproducible, CFTR...

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of...

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

Cantor Fitzgerald started coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT  Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued an...

4D Molecular Therapeutics (NASDAQ:FDMT) Receives New Coverage from Analysts at Cantor Fitzgerald

4D Molecular Therapeutics, Inc. operates as a clinical stage biotherapeutics company, which engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for ophthalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Market Cap	$623.35M
Volume (M)	312,849.00
52-Wk High	$26.49
52-Wk Low	$9.44

FDMT 4D Molecular Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community